We demonstrate that the addition of exenatide to basal insulin does not further enhance underlying beta-cell function or the capacity to achieve diabetes remission in early T2DM but does yield on-treatment glycemic and weight benefits. This evidence concerns the gene INS and type 2 diabetes mellitus.